Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-1 vs TIROSINT-SOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
Hypothyroidism, primary, secondary, or tertiary,Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
Hypothyroidism (all causes, including congenital, primary, secondary, and tertiary),Thyroid-stimulating hormone (TSH) suppression therapy (as an adjunct to surgery and radioiodine therapy for thyroid cancer)
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks.
Levothyroxine is deiodinated to liothyronine in peripheral tissues via iodothyronine deiodinases (DIO1, DIO2). Liothyronine undergoes deiodination and conjugation (glucuronidation, sulfation) in liver.
Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces.
>99% bound; T4 bound to thyroxine-binding globulin (TBG: ~70%), transthyretin (10-15%), and albumin (15-20%); T3 binds less avidly to TBG and albumin.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin.
Vd: approximately 0.1-0.2 L/kg for T4; 0.3-0.5 L/kg for T3; reflects distribution primarily into extracellular fluid and limited tissue penetration for T4, wider distribution for T3.
0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors.
Oral: 50-80% for T4 (absorption depends on formulation and food); T3 nearly completely absorbed (>90%).
Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets.
No specific GFR-based dose adjustment required; however, in severe renal failure, monitor thyroid function closely as drug clearance may be altered.
No dose adjustment required for GFR < 60 m L/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced.
No specific Child-Pugh based dose adjustment; caution in severe hepatic impairment due to altered metabolism of thyroid hormones.
No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired.
Weight-based dosing for hypothyroidism: initial 12.5-25 mcg levothyroxine equivalent per day, adjusted based on TSH and free T4 levels. Not recommended for children due to fixed combination ratio.
Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4.
Start with lower dose (e.g., half tablet) and titrate slowly; monitor for cardiac side effects due to increased sensitivity to thyroid hormones.
Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 m IU/L due to higher risk of cardiac effects.
No black box warning.
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
Cardiovascular toxicity with overdosage; may exacerbate angina, arrhythmias, hypertension. Caution in patients with diabetes mellitus (may increase blood glucose) and adrenal insufficiency. Monitor thyroid function tests and adjust dose.
Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Uncorrected adrenal insufficiency; untreated thyrotoxicosis; hypersensitivity to any ingredient; acute myocardial infarction (relative).
Avoid high-fiber foods, grapefruit juice, and soy products within 4 hours of taking Euthyroid-1 as they may interfere with absorption. Maintain consistent iodine intake; avoid drastic increases in cruciferous vegetables (e.g., broccoli, kale) without medical advice. Calcium-fortified foods and iron-rich foods should be separated by at least 4 hours.
Absorption of levothyroxine is reduced by high-fiber foods, soy products, grapefruit juice, and caffeine. Iron, calcium, aluminum- or magnesium-containing antacids, and bile acid sequestrants also inhibit absorption. Separate ingestion of TIROSINT-SOL from these substances by at least 4 hours.
EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits, preterm delivery, and low birth weight. Levothyroxine itself is not teratogenic; the FDA pregnancy category is A. No increased risk of congenital malformations has been reported with therapeutic doses. In the first trimester, adequate maternal T4 is critical for fetal brain development. In the second and third trimesters, placental transfer of levothyroxine is minimal as fetal thyroid function matures. Untreated hyperthyroidism from over-replacement may increase risk of fetal tachycardia, growth restriction, and preterm birth.
Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins.
Levothyroxine is excreted into breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. The estimated daily infant dose through breast milk is less than 1% of the maternal dose, which is negligible. No adverse effects in infants have been reported. The American Academy of Pediatrics considers levothyroxine compatible with breastfeeding. Monitoring of infant thyroid function is not routinely required but may be considered if maternal dose is high.
Levothyroxine is secreted into breast milk in minimal amounts (M/P ratio approximately 2.2). Doses up to 300 mcg/day produce negligible serum levothyroxine levels in breastfed infants. No adverse effects reported. Breastfeeding is considered safe with continued maternal therapy. Monitor infant thyroid function if maternal dose is very high.
Pregnancy increases total body water, plasma volume, and renal clearance, and alters thyroid-binding globulin synthesis, leading to increased levothyroxine requirements. Dose adjustments are often needed as early as 4-6 weeks gestation. Typically, the dose is increased by 30-50% from preconception baseline. For patients already on levothyroxine, increase dose by 2 additional tablets per week (e.g., 2 extra doses) or approximately 30% upon confirmation of pregnancy. Monitor TSH every 4-6 weeks and adjust to maintain TSH <2.5 m IU/L in the first trimester and <3.0 m IU/L in later trimesters. After delivery, reduce dose to prepregnancy level and check TSH 6 weeks postpartum.
Pregnancy increases levothyroxine requirements due to increased thyroxine-binding globulin, increased plasma volume, and placental deiodinase activity. Approximately 50-85% of patients require dose increases, often beginning at 4-8 weeks gestation. Starting dose increase: 30-50% increase in levothyroxine dose as soon as pregnancy confirmed. Monitor TSH every 4-6 weeks; adjust in increments of 12.5-25 mcg/day. Postpartum: dose typically returns to prepregnancy level within 4-6 weeks.
Euthyroid-1 contains levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Monitor TSH, free T4, and free T3 levels to avoid overtreatment, especially due to T3 component. Use with caution in elderly and patients with cardiovascular disease; start with lower doses. T3 has a shorter half-life (about 1 day) vs T4 (7 days); consider this when interpreting labs. Drug interactions: iron, calcium, antacids, and bile acid sequestrants may reduce absorption; separate by at least 4 hours.
TIROSINT-SOL is a liquid formulation of levothyroxine sodium used for patients who cannot swallow tablets, have GI absorption issues, or require precise dosing. Administer on an empty stomach (30–60 minutes before breakfast) with water only. Avoid administration with iron, calcium, or antacids within 4 hours. Monitor TSH 4–6 weeks after dose changes. Use caution in patients with cardiovascular disease; start with low doses. T4 replacement may unmask adrenal insufficiency in panhypopituitarism—screen with ACTH stimulation test if suspected.
Take exactly as prescribed at the same time each day, usually in the morning on an empty stomach with water.,Do not stop or change dose without consulting your doctor; symptoms may take weeks to improve.,Inform your doctor of all other medications and supplements you take, especially iron, calcium, and antacids.,Report symptoms of hyperthyroidism (rapid heart rate, chest pain, sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Store at room temperature away from moisture and heat; keep out of reach of children.
Take TIROSINT-SOL exactly as prescribed, usually once daily on an empty stomach, at least 30–60 minutes before eating or drinking anything except water.,Do not mix the solution with any other liquids or foods; only use the provided oral syringe for accurate dosing.,Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding, as dose adjustments may be needed.,Do not stop taking this medication without consulting your doctor, even if you feel well; thyroid hormone replacement is usually lifelong.,Store the solution in the refrigerator (36°F to 46°F) and use within 60 days after first opening; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-1 vs TIROSINT-SOL, answered by our medical review team.
EUTHROID-1 is a Thyroid Hormone Replacement that works by Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.. TIROSINT-SOL is a Thyroid hormone replacement that works by Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-1 and TIROSINT-SOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-1 is: One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.. The standard adult dose of TIROSINT-SOL is: Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-1 and TIROSINT-SOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-1 is classified as Category C. EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits,. TIROSINT-SOL is classified as Category C. Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is ass. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.